The work by Rees et al. provides evidence that the proaggregating effect exerted by AChE towards β-amyloid is active also in vivo. This conclusion supports and puts in a more interesting perspective the search for AChE inhibitors acting as bifunctional agents being able to block both the catalytic and the proaggregating actions of the enzyme (see, for example, Piazzi et al., 2003).
References:
Piazzi L, Rampa A, Bisi A, Gobbi S, Belluti F, Cavalli A, Bartolini M, Andrisano V, Valenti P, Recanatini M.
3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy.
J Med Chem. 2003 Jun 5;46(12):2279-82.
PubMed.
Comments
University of Bologna
The work by Rees et al. provides evidence that the proaggregating effect exerted by AChE towards β-amyloid is active also in vivo. This conclusion supports and puts in a more interesting perspective the search for AChE inhibitors acting as bifunctional agents being able to block both the catalytic and the proaggregating actions of the enzyme (see, for example, Piazzi et al., 2003).
References:
Piazzi L, Rampa A, Bisi A, Gobbi S, Belluti F, Cavalli A, Bartolini M, Andrisano V, Valenti P, Recanatini M. 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J Med Chem. 2003 Jun 5;46(12):2279-82. PubMed.
Make a Comment
To make a comment you must login or register.